Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2007

View Archived Issues

Avexa reports progress with apricitabine

NovaCal changes name to NovaBay

Plethora seeks clearance to begin phase III for PSD-502 in premature ejaculation

TorreyPines and Eisai extend Alzheimer's disease collaboration

Peregrine licensee begins phase I trial with TNT cancer agent

New phase I trial studies L-annamycin in pediatric ALL and AML

CUV-1647 significantly delays onset of erythropoietic protoporphyria pain

Development of AOD-9604 in obesity terminated following phase IIb results

Antitumor activity following GVAX immunotherapy + ipilimumab

Incyte updates pipeline advances

Phase III findings for Cimzia in rheumatoid arthritis

CureDM reports diabetes preclinical milestones

Valeant files IND for Cesamet in chemotherapy-induced neuropathic pain

Rosiglitazone linked to increased incidence of fractures in female patients

Novel synthetic diazonamide A analogue shows promise in preclinical studies

Therapeutic potential for prolactin inhibition in postpartum cardiomyopathy

(-)-Epigallocatechin-3-gallate lipophilic analogue shows antidiabetic activity in vitro and in vivo

Roche suspends recruitment in phase II CERA study

Avastin recommended for approvals in Japan, E.U.

Approvable letter for Galvus

Vyvanse approved for ADHD

Xeloda recommended for E.U. approval for advanced gastric cancer

Sebivo recommended for approval in E.U. for chronic hepatitis B

Recent patents disclose novel antiinfective agents

Novel agents for HIV infection reported in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...